Protocol EA2234: A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis - STOPGAP II

This study is testing if giving chemotherapy directly into the abdomen, combined with standard vein-based chemotherapy, is more effective at treating stomach cancer that has spread to the abdominal lining. Researchers want to see if this dual-delivery method helps people live longer and prevents the cancer from growing further compared to standard treatment alone.

This study is open to patients with stomach or gastroesophageal cancer that has spread to the abdominal lining. Eligibility is determined after a surgical procedure to check the abdomen, and patients must be healthy enough to undergo chemotherapy and minor surgery.

You will first have a minor surgery called a laparoscopy to examine your abdomen, which will determine your study group. Depending on your group, you will either receive standard chemotherapy or chemotherapy through a vein combined with medication delivered directly into your belly through a small port. Your medical team will monitor you closely with regular scans and check-ups for up to five years.

This study is currently recruiting patients at various medical centers in California, including locations in Irvine, Los Angeles, and Orange.